1 Result(s)

Article

Clinicopathological and molecular predictors of [¹⁸F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial

The PHERGain study (NCT03161353) is assessing early metabolic responses to neoadjuvant treatment with trastuzumab-pertuzumab and chemotherapy de-escalation using a [¹⁸Fluorine]fluorodeoxyglucose-positron emission...

Antonio Llombart-Cussac, Aleix Prat… in European Journal of Nuclear Medicine and M… (2024)